| Codiak BioSciences is a clinical-stage biopharmaceutical company focused on the development of exosome-based therapeutics. One of Co.'s clinical stage programs, exoSTING, is an exosome therapeutic candidate delivering its proprietary STING agonist while expressing high levels of Prostaglandin F2 receptor negative regulator (PTGFRN) on the exosome surface to facilitate specific uptake in tumor-resident antigen-presenting cells. Co.'s other clinical stage program, exoIL-12, displays IL-12 in an active form on the surface of the engineered exosome. Co.'s third clinical stage program, exoASO-STAT6, overexpresses PTGFRN to selectively target uptake in M2-polarized tumor-associated-macrophages. The CDAK average annual return since 2020 is shown above.
The Average Annual Return on the CDAK average annual return since 2020 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether CDAK average annual return since 2020 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CDAK average annual return calculation with any dividends reinvested as applicable (on ex-dates).